title: Pharmaceutical approval update.
abstract: Droxidopa (Northera) for neurogenic orthostatic hypotension, elosulfase alfa (Vimizim) for Morquio A syndrome, and sodium hyaluronate in phosphate-buffered saline (Monovisc) to address knee osteoarthritis.
authors.forename: Marvin M
authors.initials: MM
authors.lastname: Goldenberg